...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in gastroenterology >Update on viral hepatitis: 2008.
【24h】

Update on viral hepatitis: 2008.

机译：病毒性肝炎最新资料：2008年。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: The present review is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2007 and November 2008. RECENT FINDINGS: The incidence of acute hepatitis A and B infection has declined significantly, especially among children less than 15 years of age. Five oral antiviral agents have been approved for the treatment of chronic hepatitis B. Telbivudine is more potent than lamivudine but is associated with a high rate of antiviral resistance compared with entecavir or tenofovir. De-novo combination of lamivudine and adefovir reduces the rate of antiviral resistance compared with lamivudine monotherapy. Individualizing dose and duration of pegylated interferon and ribavirin according to on-treatment virologic response may improve sustained virologic response rates. Several specifically targeted antiviral therapies notably protease and polymerase inhibitors are promising but must be used in combination with pegylated interferon and ribavirin. Hepatitis E virus has been reported to result in chronic hepatitis in transplant patients. SUMMARY: Multiple treatment options are available for hepatitis B but long-term treatment is required. Several specifically targeted antiviral therapies have shown promise. In the meantime, individualizing dose and duration of pegylated interferon and ribavirin might improve sustained virologic response rates in patients with hepatitis C.
机译：综述的目的：本综述是对病毒性肝炎领域近期发展的简明综述，其依据是2007年12月至2008年11月之间的出版物。最新发现：急性甲型和乙型肝炎感染的发生率已大大下降，尤其是在儿童中小于15岁。五种口服抗病毒药已被批准用于治疗慢性乙型肝炎。替比夫定比拉米夫定更有效，但与恩替卡韦或替诺福韦相比，抗病毒耐药率高。与拉米夫定单药治疗相比，拉米夫定和阿德福韦的德诺伏组合可降低抗病毒耐药率。根据治疗中的病毒学应答个体化聚乙二醇化干扰素和利巴韦林的剂量和持续时间可以提高持续的病毒学应答率。几种专门针对性的抗病毒疗法，尤其是蛋白酶和聚合酶抑制剂，是有希望的，但必须与聚乙二醇化干扰素和利巴韦林联合使用。据报道，戊型肝炎病毒可导致移植患者慢性肝炎。摘要：乙型肝炎有多种治疗选择，但需要长期治疗。几种专门针对性的抗病毒疗法已显示出希望。同时，聚乙二醇化干扰素和利巴韦林的个体化剂量和持续时间可能会改善丙型肝炎患者的持续病毒学应答率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号